BioPharma Credit highlights yesterday’s announcement that Paratek has completed its purchase of OPTN. In connection with this, BioPharma Credit received $82.8m, $71.5m was the repayment of the loan it had made to OPTN and $11.3m came as ‘make-whole’ and prepayment fees, and accrued interest. There is another $1.6m to come in connection with the company’s … Continue reading BioPharma Credit lends to Paratek as it cashes out its OPTN position